Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:4
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
[31]   Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome * [J].
Allahyari, Abolghasem ;
Seddigh-Shamsi, Mohsen ;
Mahmoudi, Mahmoud ;
Jamehdar, Saeid Amel ;
Amini, Mahnaz ;
Mozdourian, Mahnaz ;
Javidarabshahi, Zahra ;
Abadi, Saeed Eslami Hasan ;
Amini, Shahram ;
Sedaghat, Alireza ;
Emadzadeh, Maryam ;
Nodeh, Mohammad Moeini ;
Rahimi, Hossein ;
Bari, Alireza ;
Mozaheb, Zahra ;
Kamandi, Mostafa ;
Azimi, Sajad Ataei ;
Abrishami, Mojtaba ;
Akbarian, Arezoo ;
Ataei, Parisa ;
Allahyari, Negin ;
Hasanzadeh, Sepideh ;
Saeedian, Neda .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 93
[32]   Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report [J].
Cesilia, Citra ;
Ridar, Elmi ;
Suryawan, Nur ;
Nataprawira, Heda Melinda .
ANNALS OF MEDICINE AND SURGERY, 2021, 72
[33]   Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China [J].
Hu, Xingsheng ;
Hu, Chunhong ;
Jiang, Dixuan ;
Zuo, Qian ;
Li, Ya ;
Wang, Yang ;
Chen, Xiangyu .
DOSE-RESPONSE, 2020, 18 (04)
[34]   Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review [J].
Munir, M. A. ;
Tandiabang, P. A. ;
Setyawati, T. ;
Basry, A. ;
Cyio, A. D. ;
Rahman, N. .
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (03) :271-275
[35]   Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires [J].
Gonzalez, Soledad E. ;
Regairaz, Lorena ;
Ferrando, Noelia S. ;
Gonzalez Martinez, Veronica V. ;
Salazar, Martin R. ;
Estenssor, Elisa .
MEDICINA-BUENOS AIRES, 2020, 80 (05) :417-424
[36]   Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions [J].
Seshan, Jayanth ;
Dube, Surya K. ;
Rajagopalan, Vanitha ;
Panda, Pragyan S. ;
Rath, Girija P. .
JOURNAL OF NEUROANAESTHESIOLOGY AND CRITICAL CARE, 2020, 7 (03) :140-147
[37]   Convalescent plasma therapy in COVID-19 and discharge status: A systematic review [J].
Agarwal, Neeraj ;
Mishra, Shradha ;
Ayub, Arshad .
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (10) :3876-3881
[38]   Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19 [J].
Dai, Weiqian ;
Gu, Haihui ;
Hao, Sha .
BLOOD SCIENCE, 2020, 2 (03) :71-75
[39]   Convalescent plasma transfusion in severe COVID-19 patients: Clinical and laboratory outcomes [J].
Abdullah, Mohd Redzuan ;
Alam Faizli, Afif ;
Adzaludin, Noor Sheereen ;
Abu Amin, Noryati ;
Misnan, Nor Arisah ;
Low, Lee Lee .
MALAYSIAN JOURNAL OF PATHOLOGY, 2023, 45 (01) :87-95
[40]   Severe refractory COVID-19 patients responding to convalescent plasma; A case series [J].
Abdullah, Hadi Mohammed ;
Hama-Ali, Hersh H. ;
Ahmed, Sabah Nasraddin ;
Ali, Kosar Muhammad ;
Karadakhy, Kamaran Amin ;
Mahmood, Safeen Othman ;
Mahmood, Zana Hameed ;
Amin, Karmand Qadir Hamad ;
Atta, Peshnyar Muhammad ;
Nuradeen, Bryar Ezadeen ;
Mohammed, Shvan H. ;
Salih, Rawezh Q. ;
Baba, Hiwa O. ;
Kakamad, Fahmi H. .
ANNALS OF MEDICINE AND SURGERY, 2020, 56 :125-127